Literature DB >> 8382288

Effect of epidermal growth factor on experimental colitis in the rat.

M S Luck1, P Bass.   

Abstract

The effect of epidermal growth factor on the rate of healing was examined in a rat model of colitis. Ulceration and inflammation of the distal colon were induced by a single intracolonic administration of 0.25 ml of 30% ethanol containing 30 mg of trinitrobenzenesulfonic acid. Epidermal growth factor was delivered intracolonically via the rectum or s.c. for 7 days after induction of colitis. Repeated s.c. injections of epidermal growth factor (25 and 100 micrograms/kg/12 hr) or continuous s.c. delivery with Alzet osmotic pumps (50 and 200 micrograms/kg/24 hr) significantly reduced colonic ulceration and inflammation. Epidermal growth factor significantly reduced myeloperoxidase activity in colonic tissue and there was restitution of the glandular mucosa after epidermal growth factor treatment. In contrast, daily intracolonic treatment with epidermal growth factor (25, 100 and 200 micrograms/kg/24 hr) did not significantly reduce the colonic damage. However, intracolonic delivery of 5-aminosalicylic acid (100 and 200 mg/kg/24 hr) dose-dependently reduced the colonic damage as assessed macroscopically and histologically. We conclude that systemic and not intracolonic administration of epidermal growth factor can accelerate healing of colonic ulceration and is effective in reducing inflammation in this model of colitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8382288

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Carbonylation and disassembly of the F-actin cytoskeleton in oxidant induced barrier dysfunction and its prevention by epidermal growth factor and transforming growth factor alpha in a human colonic cell line.

Authors:  A Banan; Y Zhang; J Losurdo; A Keshavarzian
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

2.  Growth factor mRNA expression in normal colorectal mucosa and in uninvolved mucosa from ulcerative colitis patients.

Authors:  A Chowdhury; R Fukuda; S Fukumoto
Journal:  J Gastroenterol       Date:  1996-06       Impact factor: 7.527

3.  Relation between colonic inflammation severity and total low-molecular-weight antioxidant profiles in experimental colitis.

Authors:  S Blau; R Kohen; P Bass; A Rubinstein
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

Review 4.  Animal models of inflammatory bowel disease.

Authors:  M A Bhatti; H J Hodgson
Journal:  Int J Exp Pathol       Date:  1995-10       Impact factor: 1.925

5.  EGF and TGF-beta1 gene expression in chronically rejecting small bowel transplants.

Authors:  E A Kouwenhoven; A N Stein-Oakley; P Jablonski; R W de Bruin; N M Thomson
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

6.  Effects of longterm epidermal growth factor treatment on the normal rat colon.

Authors:  P Kissmeyer-Nielsen; L Vinter-Jensen; M Smerup
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

7.  Carbachol induces TGF-alpha expression and colonic epithelial cell proliferation in sensory-desensitised rats.

Authors:  Kerem Bulut; Peter Felderbauer; Karoline Hoeck; Wolfgang E Schmidt; Peter Hoffmann
Journal:  Int J Colorectal Dis       Date:  2009-12-10       Impact factor: 2.571

8.  Morphological properties of zero-stress state in rat large intestine during systemic EGF treatment.

Authors:  Jian Yang; Jingbo Zhao; Yanjun Zeng; Lars Vinter-Jensen; Hans Gregersen
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

9.  Phorbol myristate acetate ex vivo model of enhanced colonic epithelial permeability. Reactive oxygen metabolite and protease independence.

Authors:  M C Berin; M G Buell
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

10.  Reduced susceptibility of mice overexpressing transforming growth factor alpha to dextran sodium sulphate induced colitis.

Authors:  B Egger; H V Carey; F Procaccino; N N Chai; E P Sandgren; J Lakshmanan; V S Buslon; S W French; M W Büchler; V E Eysselein
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.